Among them, Chengdu Ruiyuan Semiconductor is mainly engaged in the research and development, design, packaging and sales of power management chips, and one of its main products is DC/DC chips. A-share listed companies include Jingfeng Mingyuan, Fumanwei, Shanghai Beiling and Xidiwei, all of which have certain market share and competitiveness in the DC/DC chip market.The "Action Plan" proposes to strive to land a number of representative M&A cases in key industries by 2027, and cultivate about 10 internationally competitive listed companies in key industries such as integrated circuits, biomedicine and new materials.
Big move! Two billion M&A and restructuring funds in Shanghai have come to target the chip and pharmaceutical industries.In terms of the amount, it is necessary to form a M&A transaction scale of 300 billion yuan, activate the total assets to exceed 2 trillion yuan, and gather 3-5 professional M&A fund managers with strong industry influence. The plan also proposes to make good use of the 10 billion yuan integrated circuit design industry M&A fund and set up a 10 billion yuan biomedical industry M&A fund.
In this regard, Bu Rixin believes that "chain owners" enterprises, as market-oriented institutions, set up CVC funds and will carry out horizontal and vertical mergers and acquisitions around the upstream and downstream of key industrial chains. "This kind of M&A will help chain-owner enterprises to expand their market scale and enhance their market competitiveness, which is the most in line with the logic of M&A and the basic logic of the Action Plan to encourage chain-owner enterprises to set up CVC funds."At the end of the year, Shanghai launched a big action in the field of mergers and acquisitions. Today, the General Office of the Shanghai Municipal People's Government issued the Action Plan for Shanghai to Support the Merger and Reorganization of Listed Companies (2025-2027) (hereinafter referred to as the Action Plan).The "Action Plan" proposes to strive to land a number of representative M&A cases in key industries by 2027, and cultivate about 10 internationally competitive listed companies in key industries such as integrated circuits, biomedicine and new materials.
Strategy guide 12-14
Strategy guide
12-14